^
    Back
    Association details:
    Biomarker:SLFN11 expression
    Cancer:Small Cell Lung Cancer
    Drug:temozolomide (DNA synthesis inhibitor) +
    veliparib (ABT-888) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    384 - Detection of DNA replication blocker SLFN11 in tumor tissue and circulating tumor cells to predict platinum response in small cell lung cancer

    Published date:
    03/10/2021
    Excerpt:
    ...a clinical trial demonstrated SLFN11 predicts better clinical outcomes in SCLC patients when treated with PARP inhibitor combinations such as temozolomide and veliparib.